ライフサイエンスコーパス: continued treatment

1 tions during the previous 12 months, despite continued treatment.

2 hrombocytopenia completely resolved, despite continued treatment.

3 ity in these mice returned to normal despite continued treatment.

4 with a delayed onset and resolution despite continued treatment.

5 ation for at least 1 month; control patients continued treatment.

6 st likely to accrue the largest benefit from continued treatment.

7 onitor response, tolerance, and the need for continued treatment.

8 d to autologous stem cell transplantation or continued treatment.

9 discontinued treatment and 4.9 for women who continued treatment.

10 ponse at first assessment, 25% improved with continued treatment.

11 cutaneous atrophy followed by resistance to continued treatment.

12 In such cases, there is no benefit to continued treatment.

13 s discontinued, whereas 24 patients required continued treatment.

14 a milepost at which to reassess the need for continued treatment.

15 ts who survived at least 6 months was 88% on continued treatment.

16 ment were the most likely to gain BMD during continued treatment.

17 eginning IFN therapy or later as a result of continued treatment.

18 ered nearly normal blood counts, even during continued treatment.

19 hypertriglyceridemia in 30% of patients who continued treatment along with antilipid therapy, and mi

20 score change at 6 months and 18 months after continued treatment and changes in neurocognitive domain

21 The study began in 1997, with continued treatment and follow-up through June 1, 2011.

22 ommon daily multivitamin, began in 1997 with continued treatment and follow-up through June 1, 2011.

23 sk and intermediate-risk patients with HF as continued treatment, and more precise risk stratificatio

24 ithdrawal, even if the perceived benefits of continued treatment are not clear.

25 With continued treatment, at month 24, patients with DME with

26 group analysis, a proportion of patients who continued treatment beyond RECIST-defined first progress

27 Forty-three patients (73%) continued treatment beyond six cycles; the median cumula

28 t trimester and in 26.1% of the 92 women who continued treatment beyond the first trimester.

29 in FEV1, -5.28% [CI, -10.03% to -0.54%]) or continued treatment (change in FEV1, 1.07% [CI, -3.3% to

30 cy resulting in a live birth as patients who continued treatment; conservative methods assumed no liv

31 distinct weight maintenance approaches vs no continued treatment control following standard family-ba

32 For women receiving continued treatment, cumulative success rates are a more

33 The protocol was later amended to allow for continued treatment during the second year.

34 In patients who continued treatment for 24 weeks and could also use stab

35 astrointestinal intolerance, and 15 patients continued treatment for 6 +/- 1 year.

36 ts with objective response or stable disease continued treatment for a maximum of four courses or unt

37 had an objective response or stable disease continued treatment for a maximum of six courses.

38 s, suggesting the need for more intensive or continued treatment for a sizable proportion of youths w

39 th no detectable HCV RNA in serum at week 20 continued treatment for a total of 48 weeks and were the

40 In total, 29 patients continued treatment for at least 1 year and 18 patients

41 Continued treatment for depression among treatment-resis

42 within the earliest weeks of the disease and continued treatment for more than 10 years.

43 reatment during the following 60 days, or 3) continued treatment for more than 90 days after treatmen

44 eous coronary intervention (PCI) followed by continued treatment for one year.

45 who had objective response or stable disease continued treatment for six courses.

46 who have few treatment options and who need continued treatment for tuberous sclerosis complex and i

47 tiretroviral therapy may derive benefit from continued treatment for two reasons.

48 5 mg/day i.v. within 48 hr of transplant and continued treatment for up to 14 days; ATG was stopped o

49 With continued treatment for up to 48 or 72 hours, more than

50 All 10 patients who continued treatment had stable disease at 3 mo.

51 sporine can also improve control in MCD, but continued treatment is often needed to maintain remissio

52 However, frequent, continued treatment is required to generate and maintain

53 ffects on the CNS of infected cats, although continued treatment is required to maintain unimpaired C

54 e episodes, the illness is still active, and continued treatment is strongly recommended.

55 a chronic or recurrent course that requires continued treatment, meaning that patients must be provi

56 positively related to age and income, while continued treatment of preexisting cases was positively

57 determine whether these effects persist with continued treatment or after discontinuation of the drug

58 With continued treatment, patients with inconsistently positi

59 in less certain, but limited experience with continued treatment suggests this approach must be under

60 However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 month

61 the incidence of gout flares diminished with continued treatment, the overall incidence during weeks

62 at week 4 was clearly high enough to justify continued treatment; the rate for unimproved patients at

63 ined responses to IFN and allow the value of continued treatment to be determined early in the course

64 Patients continued treatment to progression or excessive toxic ef

65 Despite continued treatment, tumors eventually become insensitiv

66 ts with objective response or stable disease continued treatment until disease progression or unaccep

67 se with objective response or stable disease continued treatment until disease progression.

68 Of 49 patients treated, 47 (95.9%) continued treatment until month 6.

69 However, continued treatment until P8 or P10 did not prevent the

70 8 weeks of treatment; patients who responded continued treatment until they experienced tumor progres

71 Patients continued treatment until treatment failure.

72 Responding and stable patients continued treatment until tumor progression or for a rec

73 ed on quetiapine plus lithium or divalproex, continued treatment was associated with a significant ri

74 ion dual antiplatelet therapy (</=6 months), continued treatment was not associated with a difference

75 s on single-dose treatment and 10 studies on continued treatment were included.

76 Animals that continued treatment with 10 mg/kg/day in three additiona

77 high-dose clopidogrel, and those without HPR continued treatment with 75 mg of clopidogrel.

78 Three days later, patients continued treatment with 80 mg/kg hydroxyurea orally eve

79 risk of relapse in depressive disorder, and continued treatment with antidepressants would benefit m

80 We aimed to assess whether continued treatment with antipsychotics in people with A

81 s benefit emerged early and persisted during continued treatment with background antiplatelet therapi

82 , 345 entered the 24-week extension, and 296 continued treatment with belimumab in the long-term cont

83 corticoid tapering were randomly assigned to continued treatment with canakinumab or to placebo.

84 ents after asparaginase, which may be due to continued treatment with corticosteroids.

85 During 2.3 years of continued treatment with dabigatran after RE-LY, there w

86 may wish to periodically assess the need for continued treatment with daily suppressive antiviral che

87 with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with c

88 Continued treatment with doxycycline caused progressive

89 inferior to the mean change for patients who continued treatment with epoetin (-0.75 g/L, -2.26 to 0.

90 Only 4.3% of study participants continued treatment with fenofibrate following completio

91 Continued treatment with fluoxetine in patients with bul

92 persistence of BCR/ABL+ progenitors despite continued treatment with imatinib mesylate.

93 from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that in

94 ed the long-term effectiveness and safety of continued treatment with intravenous pamidronate infusio

95 ondary to renal insufficiency and eventually continued treatment with itraconazole cyclodextrin, 100

96 340 patients continued treatment with lumacaftor 400 mg every 12 h/iv

97 f less than 8% and were randomly assigned to continued treatment with metformin alone or to metformin

98 ssion were then randomly assigned to receive continued treatment with myeloablative chemotherapy, tot

99 The findings suggest that continued treatment with naltrexone may be beneficial fo

100 or neurotrophins or their receptors; and (2) continued treatment with neurotrophins fails to achieve

101 er these conditions is strictly dependent on continued treatment with NGF.

102 seline measures, patients were randomized to continued treatment with nifedipine or an equivalent dos

103 release once every 28 days for 24 weeks, or continued treatment with octreotide or lanreotide (activ

104 ide provides superior efficacy compared with continued treatment with octreotide or lanreotide, and c

105 Three responding patients continued treatment with rhuMAbVEGF and chemotherapy, re

106 Continued treatment with sertraline yielded lower PTSD r

107 articipants were offered the opportunity for continued treatment with the opiate antagonist, naltrexo

108 Continued treatment with thienopyridine, as compared wit

109 Continued treatment with TRP antagonists blocked the dev

110 nacceptable serious adverse events (safety), continued treatment without adverse event requiring dose

111 with poor initial response may benefit from continued treatment without switching to another drug.